Richards Sydney, Mu Weiyi, Nusbaum Rachel, Lincoln Katherine, Solimine Julie
Master's in Genetic Counseling Training Program University of Maryland School of Medicine Baltimore Maryland USA.
Department of Genetic Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA.
Mov Disord Clin Pract. 2023 Jan 2;10(2):248-257. doi: 10.1002/mdc3.13641. eCollection 2023 Feb.
The perspective and experiences of individuals with Parkinson's disease (PD) regarding genetic testing is limited.
To determine if anticipated benefits and negative consequences of genetic testing noted in prior studies have occurred in a surveyed group of patients with PD and to identify reasons why some individuals with PD have not had testing.
Individuals were surveyed from 22 support/advocacy groups throughout the US. Information about patient demographics and genetic testing were assessed, along with the consequences experienced after testing or anticipated by those who have not had testing. Descriptive statistics, Pearson correlation coefficient, ANOVA, and independent sample -test were utilized for data analysis.
Of the genetic testing group ( = 78), most received testing through a research study (44.9%) or a Direct-to-Consumer company (46.2%). Most did not meet with a genetic counselor before (87.2%) or after testing (64.1%). Fewer positive and fewer negative consequences were reported after testing compared to the consequences anticipated by those who have not undergone testing ( < 0.001, all comparisons). Of the non-genetic testing group ( = 166), 49.4% did not undergo testing because they were not aware it was available and 38.0% because their doctor did not offer it.
Findings demonstrate the need for providers to have genetic testing discussions with PD patients, who may otherwise seek testing via Direct-to-Consumer companies or be unaware it is available. Collaborations with genetic counselors trained in providing anticipatory guidance may assist patients in forming more realistic expectations regarding the consequences experienced after genetic testing for PD.
帕金森病(PD)患者对于基因检测的看法和经历有限。
确定先前研究中提到的基因检测的预期益处和负面后果是否在一组接受调查的PD患者中出现,并找出一些PD患者未进行检测的原因。
对来自美国22个支持/倡导团体的个体进行了调查。评估了患者人口统计学信息和基因检测情况,以及检测后经历的后果或未检测者预期的后果。采用描述性统计、Pearson相关系数、方差分析和独立样本检验进行数据分析。
在基因检测组(n = 78)中,大多数人通过研究项目(44.9%)或直接面向消费者的公司(46.2%)接受检测。大多数人在检测前(87.2%)或检测后(64.1%)没有与遗传咨询师会面。与未接受检测者预期的后果相比,检测后报告的积极后果和消极后果都更少(P < 0.001,所有比较)。在非基因检测组(n = 166)中,49.4%的人未进行检测是因为他们不知道有基因检测,38.0%的人是因为他们的医生没有提供。
研究结果表明,医疗服务提供者有必要与PD患者进行基因检测方面的讨论,否则患者可能会通过直接面向消费者的公司寻求检测,或者不知道有基因检测这回事。与接受过提供预期指导培训的遗传咨询师合作,可能有助于患者对PD基因检测后的后果形成更现实的期望。